GET DAILY SIGNALSACADIA Pharmaceuticals (ACAD) Delivers Steady Q3 2026 Revenue Growth Led by DAYBUE
Key Takeaways
- ACADIA reported third quarter 2026 total revenue of $342 million, up 22% year over year on an adjusted basis and above the consensus estimate of roughly $332 million.
- DAYBUE (trofinetide) net sales climbed 39% to $140 million, while NUPLAZID (pimavanserin) net sales rose 12% on an adjusted basis to $202 million.
- GAAP net income was $54 million, or $0.31 per diluted share, down from $72 million, or $0.42 per share, a year earlier, largely reflecting a swing in income tax expense.
- Management raised its full-year guidance for DAYBUE following European Commission approval and an early October commercial launch in Germany.
- For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
- Explore Trending AI Robots for AI-driven trading strategies and market insights.
The Earnings Context and Why It Matters
ACADIA Pharmaceuticals is a San Diego-based biopharmaceutical company focused on central nervous system disorders and rare diseases, anchored by two commercial products: NUPLAZID for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE, the first FDA-approved treatment for Rett syndrome. The third quarter of 2026 mattered to investors because it tested whether DAYBUE's new STIX formulation and an emerging European launch could extend the company's growth beyond its established NUPLAZID base. With the stock having lagged in prior quarters and SG&A spending rising to support an expanded sales force, this report offered a crucial read on whether commercial momentum could translate into durable top-line growth and improving profitability.
A Closer Look at the Reported Results
ACADIA posted third quarter 2026 total revenue of $342 million, up 22% year over year on a non-GAAP adjusted basis and ahead of the consensus estimate of approximately $332 million. The growth was driven by both franchises. DAYBUE net sales reached a record $140 million, a 39% increase, with nearly all of the growth coming from volume as uptake of the DAYBUE STIX formulation expanded — more than half of U.S. DAYBUE patients were using STIX by quarter-end. NUPLAZID net sales were $202 million, up 12% year over year on an adjusted basis, supported by healthy new-to-brand prescription trends.
On the bottom line, GAAP net income was $54 million, or $0.31 per diluted share, compared with $72 million, or $0.42 per share, in the prior-year period. The decline reflected a $26.9 million income tax expense versus a $27.2 million income tax benefit a year earlier, along with higher SG&A spending of $159 million, up from $133 million. Research and development (R&D) expenses declined to $76 million from $88 million. The company ended the quarter with $976 million in cash, cash equivalents, and investments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
The third quarter report drew a measuredly positive response, with ACAD shares trading modestly higher in after-hours activity as investors weighed the revenue beat and raised DAYBUE guidance against a year-over-year decline in GAAP net income. Sentiment centered on the durability of DAYBUE's growth, the encouraging adoption of its STIX formulation, and the significance of European Commission approval, which made DAYBUE the first and only approved treatment for the neurobehavioral symptoms of Rett syndrome in the European Union. The company's early October commercial launch in Germany — where it can price freely during reimbursement negotiations — gave investors a concrete near-term catalyst to monitor alongside continued NUPLAZID execution.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors are likely to focus on how quickly DAYBUE's European launch converts initial physician interest into sustained commercial sales. Management plans to submit reimbursement dossiers for key launch countries before year-end, and the pace of those negotiations will shape how rapidly international revenue contributes to the top line.
In the United States, the trajectory of DAYBUE STIX adoption — including patient restarts and new patient starts — remains a central growth driver, while the company reiterated its $700 million sales ambition for DAYBUE by 2028. A recently announced patent allowance extends U.S. exclusivity into 2041, supporting the franchise's longer-term outlook.
On the NUPLAZID side, watch whether the expanded field force converts stronger intent-to-prescribe signals into new-to-brand prescription growth through late 2026 and into 2027. Pipeline catalysts also loom, including clinical readouts across Alzheimer's disease psychosis and other programs, which could broaden the company's growth story beyond its two marketed products. As always, near-term results will hinge on execution rather than any single headline.
Integrating AI Tools into My Analysis Process
When reviewing earnings like these, I often turn to Tickeron’s AI Screener to quickly filter comparable names and technical setups across the sector. It helps surface ideas based on fundamentals, patterns, and performance metrics in a fraction of the time it would take manually, which is especially useful around quarterly reports when cross-checking momentum and peer trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ACAD's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ACAD turned positive on October 15, 2026. Looking at past instances where ACAD's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACAD's RSI Oscillator exited the oversold zone, 17 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on ACAD as a result. In 73 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +4.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACAD advanced for three days, in 189 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for ACAD moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACAD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
ACAD broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ACAD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. ACAD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.831) is normal, around the industry mean (2.904). P/E Ratio (9.500) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (4.168) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACAD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceuticals drugs for treatment of central nervous system disorders
Industry Biotechnology
Advertisement